Track topics on Twitter Track topics that are important to you
Unit 2, 10 Rodborough Rd
New South Wales
Phone: +61 2 9454 7200
Fax: +61 2 9451 3622
Gary Philips, CEO to Pharmaxis, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.
Pharmaxis has raised A$24m ($17.74m) in two tranches through a private placement of 73.8 million shares priced at A$0.325 ($0.24)...Read More... The post Deals this week: Pharmaxis, Almirall, Cipla Qu...
Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips updates Proactive Investors on the pharmaceutical research company’s key programs, including the latest on the anti fibrotic LOXL2 program whi...
Ed Rayner, investment director at Arix Bioscience Plc (LON:ARIX), discusses the decision to make their first investment in Australia by leading a sizeable funding round for ASX-listed Pharmaxis (ASX...
Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights. PXS472...
Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound $PXSLY http://www.pharmaxis.com.au/investor-centre/news/view/pharmaxis-releases-positive-results-of-phase-1-clinical-trial-for-second-loxl2-inhibitor-compou
Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound $PXSLY http://www.pharmaxis.com.au/investor-centre/news/view/pharmaxis-releases-positive-results-of...
Pharmaxis, an Australian pharmaceutical research company, has announced positive results from the phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being de...
UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.
These highlights do not include all the information needed to use ARIDOL safely and effectively. See full prescribing information for ARIDOL. ARIDOL™ (mannitol inhalation powder) Bronchial Challenge...
Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory diso...
Pharmaxis Ltd is a specialist pharmaceutical company established to research, development and bring to market human therapeutic products to treat chronic respiratory and autoimmune diseases. Founded ...
We have published hundreds of Pharmaxis news stories on BioPortfolio along with dozens of Pharmaxis Clinical Trials and PubMed Articles about Pharmaxis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmaxis Companies in our database. You can also find out about relevant Pharmaxis Drugs and Medications on this site too.
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...